The ROMANOV study found impaired humoral and cellular immune responses to SARSCov-2 mRNA vaccine in virus unexposed patients receiving maintenance hemodialysis.

Patients on maintenance hemodialysis (MHD), which are at high risk of infection by SARS-CoV-2 virus and death due to COVID-19, have been prioritized for vaccination. However, because they were excluded from pivotal studies and have weakened immune responses, it is not known whether these patients are protected after the “standard” two doses of mRNA vaccines. To answer this, anti-spike receptor binding domain (RBD) IgG and interferon gamma-producing CD4+ and CD8+ specific-T cells were measured in the circulation 10-14 days after the second injection of BNT162b2 vaccine in 106 patients receiving MHD (14 with hist ory of COVID-19) and compared to 30 healthy volunteers (four with history of COVID-19).

Source: Kidney International - July 17, 2021 Category: Urology & Nephrology Authors: Maxime Espi, Xavier Charmetant, Thomas Barba, Laetitia Koppe, Caroline Pelletier, Emilie Kalbacher, Elodie Chalencon, Virginie Mathias, Anne Ovize, Emmanuelle Cart-Tanneur, Christine Bouz, Laurence Pellegrina, Emmanuel Morelon, Denis Fouque, Laurent Juill Tags: clinical investigation Source Type: research